EBT-101

Phase 1Biologic

EExcision BioTherapeutics

EBT-101 is one of 6 biologic programs targeting Long-term Follow-up. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Long-Term Follow-upEnrolling by invitation

Long-Term Follow-upPhase 1

Enrolling by invitation

Competition

Competitive Landscape

5 competitors in Long-Term Follow-up

#DrugCompanyPhaseTrials

SAT-3247

SSatellos Bioscience, Inc.

Phase 2

1 2

EBT-101

EExcision BioTherapeutics

Phase 1

1 3

MB-CART19.1

MMiltenyi Biomedicine GmbH

Preclinical

1 4

MB-CART2019.1

MMiltenyi Biomedicine GmbH

Preclinical

1 5

Hearticellgram-AMI

PPharmicell Co., Ltd.

Preclinical

1 6

MB-CART20.1

MMiltenyi Biomedicine GmbH

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

HIV-11 trial

Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART

Completed·EExcision BioTherapeutics·Phase 1·NCT05144386·6 enrolled

Long-term Follow-up1 trial

Long-Term Follow-Up Study of HIV-1 Infected Adults Who Received EBT-101

Enrolling by invitation·EExcision BioTherapeutics·Phase 1·NCT05143307·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for EBT-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EBT-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EBT-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Excision BioTherapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: EExcision BioTherapeutics

EBT-101

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

HIV-11 trial

Long-term Follow-up1 trial

References

Drug Info

Quick Facts

Related News